Illumina Inc. ($ILMN) Stock Forecast: Up 5.1% Today

What is Illumina Inc.?

ILMN (Illumina Inc.) is a leading company in the genomics industry, known for its innovative solutions in next-generation sequencing and genetic analysis. Today, the stock of ILMN experienced a strong bullish movement.

Why is Illumina Inc. going up?

ILMN stock is up 5.1% on May 29, 2026 16:06

• The collaboration between Illumina and SPT Labtech to introduce the fireflyGO automation platform for targeted oncology research has generated significant excitement and positive sentiment in the market.
• The launch of new solutions by Illumina, such as the fireflyGO robot and the distributed whole-genome sequencing solution for detecting molecular residual disease in cancer research, has showcased the company's commitment to innovation and addressing critical needs in the healthcare industry.
• These advancements in automation, liquid handling, library preparation, and highly sensitive MRD research have likely contributed to investor optimism, driving the bullish movement in Illumina's stock as investors see potential for increased efficiency, accessibility, and accuracy in genomic testing and cancer research.

ILMN Price Chart

ILMN Technical Analysis

ILMN News

Illumina and SPT Labtech on fire with new collaboration

Illumina and SPT Labtech, both based in the Cambridge Cluster, have formed a new alliance, unveiling the fireflyGO automation platform at an industry show in Chicago. This benchtop liquid handling and library preparation solution integrates with the MiSeq™ i100 Series to automate and streamline workflows for targeted oncology research, making next-generation sequencing more accessible and efficient. The collaboration aims to accelerate genomics in cancer testing, reduce hands-on time, and broaden genomic testing by offering rapid results for solid tumor and hematologic malignancies.

https://www.businessweekly.co.uk/posts/illumina-and-spt-labtech-on-fire-with-new-collaboration

Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research

Illumina and SPT Labtech have introduced fireflyGO, an automation platform designed to accelerate and simplify targeted oncology research. This benchtop liquid handling and library preparation solution integrates with the MiSeq i100 Series, aiming to streamline workflows and improve the accessibility and scalability of next-generation sequencing (NGS). The platform, which automates library preparation for Pillar Biosciences' oncoReveal® targeted oncology research panels, reduces manual effort and enhances reproducibility, thereby broadening genomic testing in cancer.

https://www.prnewswire.com/news-releases/illumina-and-spt-labtech-unveil-fireflygo-enabling-faster-simpler-targeted-oncology-research-302784759.html

Illumina's new fireflyGO robot targets faster cancer lab workflows

Illumina and SPT Labtech have launched fireflyGO, a new benchtop automation platform designed to streamline liquid handling and library preparation in targeted oncology research. Integrated with the MiSeq i100 Series, fireflyGO aims to make next-generation sequencing (NGS) more accessible and efficient for cancer testing. Additionally, Illumina is expanding its oncoReveal portfolio with new gene panels for solid tumor and lymphoid malignancies, all geared towards accelerating genomic characterization of various cancer types.

https://www.stocktitan.net/news/ILMN/illumina-and-spt-labtech-unveil-firefly-go-enabling-faster-simpler-uaipih9njx2d.html

Illumina cancer research workflow spots tiny traces of disease in 5 days

Illumina has launched a new distributed whole-genome sequencing (WGS) research solution for detecting molecular residual disease (MRD) in solid tumors and blood cancers. This NovaSeq-compatible workflow can perform tumor fingerprinting and blood-based MRD detection in as little as 5 days, boasting high analytical sensitivity (10 ppm) and specificity (99.5%). Early access is currently available, with a global launch planned for next year and further ultra-sensitive solutions in development.

https://www.stocktitan.net/news/ILMN/illumina-introduces-the-first-distributed-whole-genome-sequencing-6xa9enmphnc2.html

Illumina introduces the first distributed whole-genome sequencing solution for highly sensitive MRD research

Illumina has launched a new distributed whole-genome sequencing (WGS) solution for molecular residual disease (MRD) research, designed to make highly sensitive MRD detection accessible to more labs. This solution allows for tumor fingerprinting and ctDNA tracking, optimized for analytical sensitivity as low as 10 ppm, crucial for early-stage and low-shedding tumors. Early results from academic partners like Mayo Clinic show strong performance with high concordance and correlation to clinical outcomes.

https://www.prnewswire.com/news-releases/illumina-introduces-the-first-distributed-whole-genome-sequencing-solution-for-highly-sensitive-mrd-research-302784511.html

Trending Today

Bitcoin ($BTC) Crypto Forecast: Down 6.2% Today

Tractor Supply Company ($TSCO) Stock Forecast: Down 5.4% Today

Monolithic Power Systems Inc. ($MPWR) Stock Forecast: Up 5.2% Today

Analog Devices Inc. ($ADI) Stock Forecast: Up 5.3% Today

Blink Charging Co. ($BLNK) Stock Forecast: Down 5.0% Today

ON Semiconductor Corporation ($ON) Stock Forecast: Up 6.4% Today

Shopify Inc. Class A Subordinate ($SHOP) Stock Forecast: Down 5.9% Today

Ethereum ($ETH) Crypto Forecast: Down 5.7% Today

Gartner Inc. ($IT) Stock Forecast: Down 5.1% Today

Corning Incorporated ($GLW) Stock Forecast: Up 13.8% Today

Illumina Inc. Price History

20.00.2026 - ILMN Stock was up 5.2%

• The bullish movement in Illumina's stock today is due to Medicare's decision to cover the TruSight™ Oncology Comprehensive test, enabling a clear reimbursement pathway and broadening access to precision oncology. This development is expected to significantly boost Illumina's revenue and enhance investor confidence in the company's clinical focus.
• Illumina's collaboration with major pharmaceutical companies like AstraZeneca, Merck, and Eli Lilly on the Billion Cell Atlas initiative is a testament to its dedication to advancing drug discovery and precision medicine by mapping disease biology at an unprecedented scale. This partnership underscores Illumina's leading position in genomic research and innovation, strengthening its market presence and growth potential.
• The company's integrated genomic workflow solutions for genetic disease research, which prioritize high-quality genomic data generation and interpretation, also contribute to its positive market sentiment. Illumina's holistic approach to genetic research and emphasis on scalable informatics are resonating well with investors, fueling optimism about the company's future prospects in the genomics industry.

21.00.2026 - ILMN Stock was up 5.1%

• Illumina's stock surged today following the news of securing CMS reimbursement for its TruSight Oncology Comprehensive test at $2,989.55 per test, effective January 1, 2026. This reimbursement is expected to drive adoption of the test, boosting Illumina's market share and revenue.
• The partnership with pharma giants like AstraZeneca, Merck, and Eli Lilly to map disease biology at an unprecedented scale through the Billion Cell Atlas initiative also contributed to the bullish movement. This collaboration enhances Illumina's position in the precision medicine field and strengthens its role in accelerating drug discovery processes.
• Analysts' positive outlook on Illumina's earnings growth and target price increases from firms like TD Cowen and Guggenheim further fueled investor optimism, driving the stock higher.
• Illumina's focus on offering integrated genomic workflow solutions for genetic disease research and emphasizing scalable informatics and high-quality genomic data generation also added to the positive market sentiment, showcasing the company's commitment to innovation and advancement in the genomics industry.

06.01.2026 - ILMN Stock was down 12.3%

• Despite strong Q4 2025 earnings that surpassed expectations, Illumina's stock saw a notable decline following a cautious 2026 revenue outlook.
• Investor response suggests disappointment with the company's conservative forecast for the upcoming period, despite its previous strong performance.
• Illumina's strategic focus on core sequencing, multiomics scaling, and data/software expansion is contributing to its momentum. However, concerns around the subdued 2026 revenue guidance seemed to overshadow these accomplishments for investors.
• While the company remains optimistic about the growing adoption of sequencing-based diagnostic tests and the NovaSeq X instrument in clinical settings, these positive prospects were unable to offset worries about future growth potential, resulting in a bearish trend for the stock.

06.01.2026 - ILMN Stock was down 9.6%

• Despite surpassing Q4 earnings forecasts, Illumina's stock trended bearishly due to its conservative 2026 revenue guidance, disappointing investors who were anticipating a more aggressive outlook.
• The market's response suggests that investors are evaluating Illumina's robust operational performance in Q4 against its unchanging annual revenue for 2025, which paralleled the previous year.
• Although Illumina offered a positive forecast for 2026, anticipating revenue growth of 4-6% and adjusted EPS of $5.05-$5.20, the stock's decline indicates that investors possibly anticipated more ambitious future projections.
• The contrast between the company's solid financial performance and the market's reaction underscores the significance of managing investor expectations and articulating a compelling growth narrative for forthcoming results.

27.02.2026 - ILMN Stock was down 5.9%

• Illumina's stock experienced a bearish movement due to regulatory scrutiny over its past Grail acquisition and a slowdown in the biotech sector, leading to softening demand in genomic sequencing and increased competition.
• The short-term corrective bearish wave, negative pressure from technical indicators like the 50-day SMA and overbought Stochastic indicators, contributed to the decline in Illumina's stock price.
• Despite positive news such as Nordea Investment Management AB significantly increasing its stake in Illumina and the company reporting strong Q4 earnings, the mixed analyst sentiment and challenges in the industry have put pressure on the stock.
• The launch of Illumina's TruPath™ Genome tool aims to provide deeper insights into complex genomic regions, showcasing the company's commitment to advancing genomic research amidst market challenges.

24.01.2026 - ILMN Stock was up 5.6%

• The positive outlook on the genomics market and the company's advancements in technology and informatics are driving the bullish movement in Illumina's stock today.
• Illumina's pivotal role in genomic projects like the UK Biobank, as highlighted in an interview with Rami Mehio, underscores their expertise and contributions to the field.
• Despite recent insider selling by SVP Patricia Leckman, investors remain confident due to the company's aggressive share buybacks and robust financial health score.
• Anticipated growth in the global genomics market and Illumina's potential revenue expansion through acquisitions like SomaLogic are likely factors boosting investor optimism and contributing to the current bullish trend.

30.03.2026 - ILMN Stock was up 5.4%

• Illumina Inc. experienced a bullish trend today, with its stock price advancing by 1.95% to $127.88, breaking a recent losing streak.
• The anticipation of the Q1 2026 earnings release created positive sentiment among investors, who were eager to receive updates on core sequencing revenue and guidance.
• The revision in Illumina's stock evaluation, showcasing strong financial metrics like a P/E ratio of 36 and a robust ROCE of 28.32%, likely contributed to the bullish movement.
• The projected growth in the Human Microbiome Sequencing Technology market, where Illumina is a key player, could have also influenced investor optimism, especially with the company's focus on innovation and strategic partnerships in the sector.

01.04.2026 - ILMN Stock was up 5.2%

• Better-than-expected Q1 2026 earnings were reported by Illumina, surpassing analyst estimates for revenue and non-GAAP EPS. This was driven by high demand for sequencing consumables and instruments in clinical applications.
• The company increased its full-year 2026 guidance, showing confidence in ongoing growth, notably in clinical markets, despite supply chain challenges and caution in research sectors.
• Although there was a slight decline after the earnings announcement, Illumina's effective operations and promising future suggest a positive quarter for investors. After-hours trading saw a 5.29% increase, outperforming competitors on a strong trading day.
• Illumina's introduction of a new $1.5 billion share repurchase program underscores its faith in the business strategy and financial outlook, bolstering positive market sentiment and the rise in the stock price.

23.03.2026 - ILMN Stock was down 5.3%

• Illumina Inc. (ILMN) saw a 1.34% increase in its stock value, falling behind its industry peers, possibly indicating weaknesses in its competitive position.
• The stock's fifth consecutive day of gains may have prompted investors to take profits, leading to downward pressure on its price.
• Despite positive performances in the market with the S&P 500 and Dow Jones Industrial Average both rising, the decline in Illumina's stock could be attributed to internal factors rather than broader market trends.

29.03.2026 - ILMN Stock was down 5.2%

• The downward trend in Illumina's stock today could be due to profit-taking following a recent increase in value.
• Insider selling by Universal Beteiligungs und Servicegesellschaft mbH may have influenced market sentiment, leading to a decrease in the stock price.
• Despite strong financial metrics and outperforming competitors on Friday, consecutive days of losses and broader market trends may have contributed to the downward movement.
• Competition in the Human Microbiome Sequencing Technology market, where Illumina is a prominent player, could also be impacting investor sentiment and trading patterns.

29.04.2026 - ILMN Stock was up 5.1%

• The collaboration between Illumina and SPT Labtech to introduce the fireflyGO automation platform for targeted oncology research has generated significant excitement and positive sentiment in the market.
• The launch of new solutions by Illumina, such as the fireflyGO robot and the distributed whole-genome sequencing solution for detecting molecular residual disease in cancer research, has showcased the company's commitment to innovation and addressing critical needs in the healthcare industry.
• These advancements in automation, liquid handling, library preparation, and highly sensitive MRD research have likely contributed to investor optimism, driving the bullish movement in Illumina's stock as investors see potential for increased efficiency, accessibility, and accuracy in genomic testing and cancer research.

28.04.2026 - ILMN Stock was up 5.1%

• The rise in Illumina Inc. (ILMN) stock value could be attributed to various factors:
• Strong annual meeting outcomes, which included the re-election of all board members and a high level of shareholder trust in the company's leadership and strategic vision.
• The addition of David King, an experienced figure in diagnostics, to the Board of Directors, demonstrating a commitment to integrating genomics in medical decisions and fostering collaborations.
• Financial evaluations showcasing ILMN's robust revenue distribution, profitability margins, and competitive stance relative to industry peers.
• Despite some cautious analyst perspectives and a "Hold" recommendation, the emergence of new institutional investments from North Star Asset Management suggests a growing confidence in Illumina's business model and growth opportunities.